Source: Annual Congress 2012 - The promise of new drugs for treating asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P.J. Barnes (London, United Kingdom). Reversing glucocorticoid resistance as a new therapeutic strategy. Annual Congress 2012 - The promise of new drugs for treating asthma and COPD

Member's Comments

No comment yet.

Related content which might interest you: Antimicrobial resistance and new therapeutic options Source: Virtual Congress 2021 – Community-acquired pneumonia: the new perspective in the post-COVID era Year: 2021 EGFR-inhibition: resistance mechanisms and new strategies Source: International Congress 2014 – Update on lung cancer biology for clinicians Year: 2014 When and how to identify resistance mechanisms to targeted therapies Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine Year: 2019 How to disrupt malicious LC-fILD pathways: antifibrotic agents as a promising therapeutic approach Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists Year: 2021 Targeting metabolic reprogramming as a novel anti-fibrotic strategy Source: International Congress 2019 – Metabolic alterations as a driver of chronicity in lung disease Year: 2019 Reversing corticosteroid resistance Source: Annual Congress 2009 - Emerging trends in the therapy of COPD Year: 2009 Rational use of tuberculosis drugs to prevent the development of drug resistance Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012 Does acute and persistent metabolic dysregulation in COVID-19 point to novel biomarkers and future therapeutic strategies? Source: Eur Respir J, 59 (2) 2102417; 10.1183/13993003.02417-2021 Year: 2022 Late Breaking Abstract - Anti-inflammatory activity of novel transtilbene sulfonamide analogues as potential novel therapeutic agents for inflammatory lung disease Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019 Targeting neuropeptide receptors by substance-P analogues identifies a strategy to develop novel anti-cancer therapies Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Predicting outcomes and drug resistance with new standardised treatment Source: Eur Respir J 2011; 37: 974 Year: 2011 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700173; DOI: 10.1183/13993003.00173-2017 Year: 2017 Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis Source: Eur Respir J , 49 (4)  1700317; DOI: 10.1183/13993003.00317-2017 Year: 2017 Do we have any alternative therapeutic option beyond antibiotics? Source: Postgraduate course 2021: PG7 - Postgraduate course : Emerging infectious diseases and antimicrobial resistance: diagnostics, treatments, vaccines and other preventive and/or therapeutic interventions Year: 2021 Optimizing the target therapy development Source: ERS Research Seminar Year: 2015 Antibiotics as immunomodulators: a potential pharmacologic approach for ARDS treatment Source: Eur Respir Rev, 30 (162) 210093; 10.1183/16000617.0093-2021 Year: 2021 COVID-19 conundrum: clinical phenotyping based on pathophysiology as a promising approach to guide therapy in a novel illness Source: Eur Respir J, 56 (2) 2002135; 10.1183/13993003.02135-2020 Year: 2020